Metabolic Tumor Volume by ¹⁸F-FDG PET/CT Can Predict the Clinical Outcome of Primary Malignant Spine/Spinal Tumors

Table 2

Factors affecting progression-free survival in the univariate and multivariate analyses.

Factor	Cut-off value	Univariate	Multivariate
		value	HR	95% CI	value
MTV	45 ml	0.04	14.6	1.78–333	0.01
TLG	150 SUVml	0.12
Size	5 cm	0.05	2.97	0.69–11.8	0.14
Surgery	Yes	0.78
Surgery with wide margin	Yes	0.42
Chemotherapy	Yes	0.03	1.67	0.50–5.69	0.40
Radiotherapy	Yes	0.36

HR: hazard risk. 95% CI: 95% confidence interval. Progression-free survival was negatively associated with the administration of chemotherapy (), which may indicate the aggressiveness of the tumors of the patients who had chemotherapy.